Kantharia B K, Goulding N J, Hall N D, Davies J, Maddison P J, Bacon P A, Farr M, Wojtulewski J A, Englehart K M, Liyanage S P
Royal National Hospital for Rhematic Diseases, University of Bath, UK.
Br J Rheumatol. 1989 Apr;28(2):118-23. doi: 10.1093/rheumatology/28.2.118.
A randomized control trial of TP-5 in rheumatoid arthritis is reported. In a multicentre study, 76 patients were treated with TP-5 50 mg or placebo three times a week for 3 weeks as a slow intravenous injection, and followed for 7 weeks. Clinical parameters such as the Ritchie index and sum score of swollen joints improved significantly on TP-5 compared to placebo. Laboratory parameters did not change but an increased skin test score to common recall antigens was observed. Toxicity was minimal. TP-5 is a potentially useful agent in the treatment of rheumatoid arthritis, although further studies are required to determine the optimal treatment regimen.
本文报道了一项关于TP - 5治疗类风湿性关节炎的随机对照试验。在一项多中心研究中，76例患者接受每周三次、每次50mg的TP - 5或安慰剂缓慢静脉注射治疗，为期3周，并随访7周。与安慰剂相比，TP - 5治疗后，诸如里奇指数和关节肿胀总分等临床参数有显著改善。实验室参数没有变化，但观察到对常见回忆抗原的皮肤试验评分增加。毒性极小。TP - 5在类风湿性关节炎治疗中可能是一种有用的药物，不过还需要进一步研究以确定最佳治疗方案。
